Salivary gland cancer treatment choices

Overview of Salivary Gland Cancer

Salivary gland cancer is an uncommon head and neck cancer that starts in the parotid gland and causes a painless lump in the mouth or jaw. Malignant salivary gland tumors that help digestion and oral health. Radiation, chemotherapy, or targeted therapies may be needed for advanced instances, although early detection and surgery are ideal. Present in ~1% of head and neck cancers, mostly benign, but with some significant malignant instances.

Common spots:

• Most common, in front of the ears: parotid glands
• Under-jaw glands.
• Under-tongue glands
• Small salivary glands (roof, lips, cheeks, sinuses, larynx).

Symptoms

• No pain in the mouth, jaw, or neck mass.
• Numb or weakened face.
• Constant jaw or face ache.
• Swallowing or mouth-opening issues.
• Mouth bleeding.

Causes and Risks

• Radiation from head/neck therapy.
• Use of tobacco and alcohol.
• People over 55 are at higher risk.
• Leatherwork, plumbing, asbestos mining, and rubber manufacture are dangerous.
• Both Epstein-Barr and HPV are associated but not established causes.

Diagnosis

• Exam for tumors and nerve function.
• CT, MRI, and PET scans for tumor size and dissemination.
• Biopsy: Fine-needle aspiration or core biopsy (only for cancer confirmation).
• Tumor size, lymph node involvement, and metastasis determine staging.

Treatment Choices

• Surgery: Primary treatment, perhaps lymph node removal.
• Radiotherapy: Photon or neutron beams.
• For advanced or metastatic instances, chemotherapy.
• Targeted therapy: Medication for genetic mutations (HER2-positive cancers).
• Immunotherapy: Studying checkpoint inhibitors.
• Advanced illness palliation.

Prognosis

• Possible cure if caught early.
• Tumor type, size, spread, and health affect survival.
• Slow-growing adenoid cystic cancer with nerve dissemination and recurrence.
• Mucoepidermoid carcinoma: Most prevalent; grade-dependent prognosis.

Prevention

• Stop smoking and drink less.
• Avoid overexposure to radiation.
• Routine oral exams for early detection
• Protection in high-risk jobs.

First signs of salivary cancer?

• Early Warning Signs
• Most common: painless cheek, jaw, lip, neck, or mouth mass.
• Face/neck swelling/asymmetry.
• One-sided facial drooping.
• Face tingling or numbness.
• Chronic mouth, jaw, ear, or neck pain.
• Swallowing or mouth-opening issues.
• Unhealing mouth or lip ulcer.
• Parotid gland-related ear leakage.

Why These Signs Matter

• Early detection greatly increases survival.
• Many of these symptoms may result from benign tumors or infections, but you should take persistent or increasing signs seriously.
• A growing painless tumor or facial nerve weakness/numbness is serious.

What To Do

• If these changes last more than 2–3 weeks, see a doctor.
• The diagnosis requires CT/MRI and biopsy.
• Surgical removal early improves cure rates.

Also read https://www.bccancer.bc.ca/health-info/types-of-cancer/head-neck/salivary-glands.

Stages of salivary gland cancer?

Tumor size, tissue spread, lymph node involvement, and distant metastasis classify salivary gland cancer from 0 to IV. Early stages (0–II) are limited and curable, while advanced stages (III–IV) entail bigger tumors, lymph nodes, or distant organs.

AJCC TNM Staging

• TNM is used by doctors:
• T: Primary tumour size and extent.
• Spread to the regional lymph nodes.
• Metastasis: Spread to other organs.

Salivary Gland Cancer Stages

• Stage Description: Key Features
• Stage 0: Duct lining cell cancer without dissemination.
• Stage I: Localized tumor. ≤2 cm, gland-confined, no lymph nodes/distant spread.
• Stage II: Localized 2–4 cm tumor with no lymph nodes or distant dissemination.
• Stage III: Locally progressed, >4 cm or invading neighboring tissues; or disseminated to ≤3 cm lymph node on the same side.
• Stage IVA: Regionally advanced. Tumors can spread to surrounding structures (e.g., jaw, skin, nerves) or numerous lymph nodes ≤6 cm
• Stage IVB: High regional spread. Tumor invades the base of the skull, carotid artery, or lymph nodes >6 cm with extranodal extension.
• A distant metastasis. Cancer has spread to the lungs, bones, and liver.

Prognosis by Stage

• Early stages (0-II): High surgery ± radiation cure rates.
• Stage III–IVA: High recurrence risk requires aggressive treatment.
• Advanced disease; systemic therapy and palliative care may be needed.

Why Staging Matters

• Helps plan surgery, radiation, chemotherapy, and targeted therapy.
• Helps predict survival.
• Assesses clinical trial eligibility.

Salivary gland cancer stage-specific treatments

Salivary gland cancer treatment depends on stage, combining surgery, radiation, and systemic therapy. A clear breakdown:

Staged Treatments

• Stage: Main Treatment Notes
• Operation (local excision) for stage 0 carcinoma. Removes aberrant cells before invasion.
• Stage I (≤2 cm, confined): Surgery (parotidectomy or gland removal). Usually curative, radiation is only utilised when margins are questionable.
• Surgery and potential radiation therapy are recommended for stage II (2–4 cm, restricted). Radiation lowers recurrence.
• Surgery and radiotherapy are recommended for stage III cancer, which is defined as a tumor larger than 4 cm or with local spread or small lymph nodes. Potential neck dissection if lymph nodes are implicated.
• The regional spread involves many lymph nodes, and stage IV requires surgery, radiation, and chemotherapy as part of a multimodal strategy.
• To treat stage IV B (deep invasion or big lymph nodes), use radiation and chemotherapy if unresectable. Control first, surgery if possible.
• Distant metastases stage IVC: Systemic therapy (chemotherapy, targeted therapy, immunotherapy) + palliative care. Symptom alleviation and life extension are goals.

Additional Methods

• Therapeutic targeting for HER2-positive or other genetic alterations.
• Immunotherapy: Advanced/recurrent checkpoint inhibitors.
• After tumor excision, reconstructive surgery restores facial function and appearance.
• Speech therapy and rehabilitation: Aids nerve and muscle healing.

Saliva cancer detection?

Advanced saliva biomarker testing detects cancer. Researchers have found tumour-derived DNA, RNA, proteins, and metabolites in saliva that can indicate oral, throat, and systemic malignancies. Although promising, saliva-based cancer screening is still experimental and not yet commonplace.

How Saliva Detects Cancer

• Tumour biomarkers: Saliva contains ctDNA, cfDNA, RNA transcripts, proteins, and metabolites that indicate cancer activity.
• Tumour exosomes go through the bloodstream to the salivary glands and deposit oncogenic material.
• Alterations in oral bacteria and host RNA profiles can indicate oral and throat malignancies.

Methods Used

• Liquid biopsy: Non-invasive saliva biomarker test.
• Tumor DNA detection is sensitive with EFIRM technology.
• NGS: Finds cancer-causing genomic alterations.
• Proteomic tests detect malignancy-associated protein levels.

Cancer Types Studied

• Oral cancer (leading research).
• Saliva RNA signatures for throat cancer.
• Early trials suggest saliva biomarkers may aid pancreatic, lung, and breast malignancies.

Limitations

• Research and clinical trials are still on for saliva tests.
• Diet, oral hygiene, and illnesses affect saliva composition.
• Reproducibility issues: Standardised collection and biomarker panels are being refined.

Future View

• Non-invasive, cost-effective, and accessible saliva-based diagnostics could become common cancer screening methods.
• Saliva testing may increase cancer survival by detecting tumors before symptoms arise.

Curable salivary gland cancer

Early detection and surgery can cure salivary gland cancer. The stage, tumor type, and spread of the malignancy determine the cure rate. Early-stage gland tumors frequently have favorable results, but advanced cases may require multimodal therapy and have a higher recurrence rate.

Curability Factors

Stage of cancer:

• Surgery alone or surgery + radiation cures stage I–II.
• Stage III–IVA: Aggressive surgery, radiation, and occasionally chemotherapy cure.
• Level IVB–IVC: Systemic therapy and management are needed; cure unlikely.

Type of tumor:

• Lower-grade mucoepidermoid carcinoma is common and treatable.
• Adenoid cystic carcinoma (slow-growing yet recurrent and nerve-spreading).
• Acinic cell cancer (favorable prognosis).
• After surgery, clear margins improve cure rates.
• Health: Younger, healthier individuals tolerate vigorous treatment better.

Hope for Survival

• Localized disease: 5-year survival frequently exceeds 90%.
• Regional spread: Survival declines to ~70%.
• Due to distant metastasis, survival is 40% or less, depending on tumor type.
• Recurrence risk: Adenoid cystic carcinoma may return decades later, needing long-term monitoring.

Challenges and Risks

• Surgery-related facial nerve injury (particularly parotid gland tumors).
• After successful therapy, adenoid cystic cancer recurs.
• Radiation side effects (dry mouth, swallowing problems).

Conclusion

Salivary gland cancer is rare, but it is treatable if caught early. Surgery is the main treatment, sometimes with radiation for advanced stages. Stage, tumour type, and metastasis are key factors in determining outcomes. Because some kinds, like adenoid cystic carcinoma, can return decades later, long-term surveillance is necessary. A cure requires early discovery and treatment, while advanced cases require continued management and support.